Exenatide: difference between revisions
Diff·revision 14 → 15·15:34, 12 Apr 2025
Difference between revision 14 and revision 15 of Exenatide. 2 lines changed; the page grew by 161 bytes.
| Revision 14 — 20:52, 30 Mar 2025 CagriCass (talk) unpipe a link that did not need piping 4,288 bytes ±0 | Revision 15 — 15:34, 12 Apr 2025 OrforglipronOona (talk) expand §The extended-release formulation 4,449 bytes +161 | ||
|---|---|---|---|
| 33 | Concentrations rise slowly over six to seven weeks to a plateau, so the full effect of starting treatment is not seen for around two months, and concentrations decay over a comparable period after stopping. Neither the onset nor the offset can be accelerated. A distinctive injection-site nodule occurs in a substantial minority of recipients, attributable to the polymer matrix rather than to the peptide. | 33 | Concentrations rise slowly over six to seven weeks to a plateau, so the full effect of starting treatment is not seen for around two months, and concentrations decay over a comparable period after stopping. Neither the onset nor the offset can be accelerated. A distinctive injection-site nodule occurs in a substantial minority of recipients, attributable to the polymer matrix rather than to the peptide. |
| 34 | 34 | ||
| + | 35 | The suspension also requires reconstitution and vigorous mixing immediately before injection, a preparation burden that later single-solution products removed. | |
| + | 36 | ||
| 35 | == References == | 37 | == References == |
| 36 | {{reflist}} | 38 | {{reflist}} |